Sino Biological Inc.

What they make

1 input Sino Biological Inc. supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Incident2020

  When SARS-CoV-2 was identified in January 2020, Sino Biological (Beijing) produced recombinant SARS-CoV-2 spike protein and nucleocapsid antibodies within weeks — faster than any Western competitor. Multiple Western lateral flow test manufacturers sourced their COVID capture and detection antibodies from Sino Biological during the 2020-2021 testing surge. This meant that competing US and European COVID test brands in pharmacies had the same Chinese-sourced antibody pairs inside the test cassette. Sino Biological supplied a critical component to both sides of the diagnostic "competitive" market simultaneously.

  Sino Biological Inc. ↗

• Did you know2023

  During the COVID-19 pandemic, Sino Biological — a Chinese biotech company in Beijing — became the dominant supplier of SARS-CoV-2 capture and detection antibodies to Western rapid antigen test manufacturers. Abbott, SD Biosensor, Innova Medical, and other major COVID rapid test brands sourced their test-critical antibody pairs from Sino Biological's catalog or custom orders. This meant that US and European COVID testing programs — positioned as critical national security infrastructure — depended on diagnostic antibodies from a Beijing company. The geopolitical exposure was significant: a US executive order or Chinese export restriction on diagnostic antibodies could have disrupted COVID testing capacity months into the pandemic. The same pattern continues: Sino Biological is a dominant supplier of PD-1, PD-L1, and other immune checkpoint proteins used as research tools by US/EU pharma companies developing the next generation of cancer immunotherapy drugs.

  Sino Biological Inc. ↗

• Capacity2023

  Sino Biological's recombinant cytokine and growth factor catalog — IL-6, TNF-alpha, IFN-gamma, and 500+ similar proteins — are the reagent tools used in virtually every cancer immunotherapy research program at major Western pharma companies. When Merck (Keytruda) or BMS (Opdivo) researchers test new PD-1 inhibitor candidates, they compare results against reference PD-1 and PD-L1 proteins. Many of those reference proteins are from Sino Biological's catalog. Pfizer, AstraZeneca, Genentech and virtually every immunology drug developer buy research-grade cytokines and checkpoint proteins from Sino Biological as basic laboratory reagents. The development of new cancer immunotherapy drugs in the United States depends, as a practical matter, on research reagents produced by a Beijing-based company — a supply chain dependency that regulators and pharma executives rarely discuss publicly.

  Sino Biological Inc. ↗

• Origin2023

  Sino Biological was founded in 2007 in Beijing by a team of Chinese biologists trained in the US and China, with the explicit goal of becoming the fastest provider of recombinant proteins and monoclonal antibodies for research and diagnostics. The company built production platforms in HEK293, Sf9 (baculovirus), and E. coli expression systems with emphasis on speed — reducing protein development timelines from the 3-6 month industry norm to 4-8 weeks. This speed advantage was unremarkable in normal times but became critical during COVID-19: when SARS-CoV-2 emerged, Sino Biological had validated spike and nucleocapsid proteins available within weeks of the genome being published, while Western competitors took months. This made Sino Biological the fastest-to-market supplier of COVID diagnostic reagents, enabling Western test kit manufacturers to launch COVID rapid antigen tests months earlier than would otherwise have been possible.

  Sino Biological Inc. ↗